---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-141756"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:39:44.404458+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre reports positive Phase 1 data for SPY002 & SPY072; half-life ~75 days, Phase 2 trials initiated

## Summary
- SPY002 and SPY072 well tolerated up to 1500 mg; no serious AEs, no TEAEs >Grade 2, no discontinuations.
- SPY002 half-life ~75 days (≥3x first-gen anti-TL1As); supports quarterly or twice-yearly SC dosing.
- Single 100 mg dose of either antibody suppressed free TL1A below LLOQ through 20 weeks.
- SKYLINE-UC (UC) platform trial started May 2025; SKYWAY-RD basket (RA, PsA, axSpA) planned Q3 2025.
- Expects 9 Phase 2 readouts by 2027; cash runway into H2 2028.

## SEC filing metadata
- accession: 0001193125-25-141756
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312525141756/0001193125-25-141756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312525141756/d18728d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-141756
- JSON: https://secwatch.observer/filing/0001193125-25-141756.json
- Plain text: https://secwatch.observer/filing/0001193125-25-141756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.